Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

INTRODUCTION: Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoid arthritis (RA). This 2-year extension study of two global phase IIb trials investigated the long-term safety and effectiveness of peficitinib. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C., Greenwald, Maria W., Gutierrez-Ureña, Sergio R., Cardiel, Mario H., Poiley, Jeffrey E., Zubrzycka-Sienkiewicz, Anna, Codding, Christine E., Wang, Annie, He, Weizhong, Amos, Rebecca, Vinueza, Raul, Wang, Xuegong, Garg, Jay P., Kivitz, Alan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858430/
https://www.ncbi.nlm.nih.gov/pubmed/31410787
http://dx.doi.org/10.1007/s40744-019-00167-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858430/
https://www.ncbi.nlm.nih.gov/pubmed/31410787
http://dx.doi.org/10.1007/s40744-019-00167-6

Ejemplares similares